One-Shot gene therapy aims to fix rare genetic disorder

NCT ID NCT06332807

Summary

This early-stage study is testing a new one-time gene therapy called NGGT002 for adults with classic phenylketonuria (PKU). The goal is to see if delivering a working copy of the faulty gene is safe and can lower harmful blood levels of phenylalanine, potentially reducing the need for a strict lifelong diet. Up to 12 participants will receive a single infusion and be followed for five years.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHENYLKETONURIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Atlantic Health System

    RECRUITING

    Morristown, New Jersey, 07960, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Children's Hospital of Orange County Hospital

    RECRUITING

    Orange, California, 92868, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55454, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Pittsburgh Medical Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University or Texas, Southwestern medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.